undamentalytics Newsletter
Sign in

Prokidney Corp. income statement

In fiscal 2025, Prokidney Corp. reported revenue of $893,000, up 1075.0% on the year before, operating income of −$165m (a -18477.8% margin) and net income of −$69.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00011
Research and development82107128114131
General and administrative7145565247
Operating income−153−152−184−165−177
Interest expense00000
Income before tax−147−129−164−151−167
Income tax16−10−1
Net income−148−35−61−69−84
Diluted EPS−$0.23————
Diluted shares (average)62m————
EBITDA−150−148−178−158−171

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MNOV vs PROKPROK vs STTKLGVN vs PROK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prokidney Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prokidney Corp.